Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics (Nasdaq: DMAC) reported dosing the first two patients in an investigator-sponsored Phase 2 trial of DM199 for early-onset fetal growth restriction (FGR). The open-label, single-arm study will assess three dose levels in up to 30 patients. DM199 aims to improve maternal uterine blood flow without crossing into fetal circulation. DiaMedica also released a white paper reviewing the scientific basis for DM199 in FGR.
DiaMedica Therapeutics (Nasdaq: DMAC) received written FDA feedback on nonclinical data needed to advance DM199 for preeclampsia. The FDA indicated a prior rat reproductive toxicity study may support a U.S. IND if drug exposure, enzymatic activity, and pharmacologic effect in rats are adequately demonstrated.
DiaMedica will run a new rat pharmacokinetic and activity study, summarize recent data, and submit the package to FDA, while planning to initiate a preeclampsia study in Canada and the UK later in 2026.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharma company focused on preeclampsia, fetal growth restriction and acute ischemic stroke, will present at the Jefferies Global Healthcare Conference 2026 in New York.
The corporate presentation is scheduled for Thursday, June 4, 2026 at 3:45 PM ET.
DiaMedica Therapeutics (Nasdaq: DMAC) reported that its pivotal Phase 2/3 ReMEDy2 trial of DM199 in acute ischemic stroke has reached 75% of the 200-patient enrollment needed to trigger a pre-specified interim analysis.
An independent DSMB will review the first 200 patients before year-end 2026 and may recommend a final sample size between 300 and 728 patients. ReMEDy2 is a randomized, double-blind, placebo-controlled study, with stroke recovery at Day 90 (mRS 0–1) as the primary endpoint. Approximately 70 sites are active across the United States, Canada, the United Kingdom and Europe.
DiaMedica Therapeutics (Nasdaq: DMAC) will participate in the 2026 RBC Capital Markets Global Healthcare Conference in New York City. President and CEO Rick Pauls is scheduled for a fireside chat on Tuesday, May 19, 2026, from 4:05–4:30 PM ET, with additional one-on-one investor meetings available.
DiaMedica Therapeutics (NASDAQ: DMAC) reported first quarter 2026 results and clinical updates on May 6, 2026. The company had $51.3 million in cash and short-term investments as of March 31, 2026, and expects runway through 2027. ReMEDy2 AIS trial enrollment surpassed 70%, with an interim analysis planned in 4Q 2026. Multiple preeclampsia (PE) and fetal growth restriction (FGR) investigator-sponsored and Phase 2 programs are active, with several readouts and a UK CTA planned in 2Q 2026.
DiaMedica Therapeutics (Nasdaq: DMAC) will release first quarter 2026 financial results after market close on May 6, 2026, and host a business update conference call on May 7, 2026 at 8:00 AM ET.
Webcast access, dial‑in details, replay instructions through May 14, 2026, and a 12‑month on‑demand webcast availability are provided. DiaMedica focuses on treatments for preeclampsia, fetal growth restriction and acute ischemic stroke; lead candidate DM199 is a recombinant KLK1 therapeutic.
DiaMedica Therapeutics (Nasdaq: DMAC) reported full-year 2025 results and a business update. Key highlights include $59.9M cash and short-term investments, runway through 2H 2027, Health Canada clearance to start a Phase 2 DM199 trial in Canada, and ReMEDy2 AIS trial near 70% enrollment for interim analysis in 2H 2026.
R&D and operating cash use increased in 2025 as clinical programs expanded; management will host a webcast on March 31, 2026.
DiaMedica Therapeutics (Nasdaq: DMAC) will release full-year 2025 financial results after market close on March 30, 2026 and will host a business update and conference call on March 31, 2026 at 7:00 AM CDT.
Investors can join via webcast or dial-in; the webcast will be available for playback on the company's investor relations site for 12 months and a telephonic replay is available through April 7, 2026. DiaMedica is a clinical-stage biopharma developing DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke.
DiaMedica Therapeutics (Nasdaq: DMAC) received a No Objection Letter from Health Canada to start a Phase 2 study of DM199 for early-onset preeclampsia. The open-label, dose-ranging trial targets pregnancies at 24–32 weeks, will test three subcutaneous dose levels every three days until delivery, and is planned to start in 2026 with expansion into the United States and United Kingdom as additional regulatory clearances are obtained. The study will assess safety, tolerability and exploratory biomarkers including uterine artery pulsatility index, sFlt-1 and placental growth factor.